SCHEMBL16748602

SCHEMBL16748602

Nc1ccccc1Nc1nncc(Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 9/20 0.47
MAPT P10636 5/20 0.45
GAA P10253 4/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAB9A P51151 1/20 0.45
KCNH2 Q12809 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GFER P55789 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK8 P45983 1/20 0.42
KDR P35968 1/20 0.41
PTGS1 P23219 2/20 0.41
TP53 P04637 1/20 0.40
APP P05067 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16747849 0.82 SCN5A (0.57) BMI1MAPTGAAALDH1A1SMN1; SMN2
SCHEMBL29824523 0.78 MAPT (0.68) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL15875869 0.78 MAPT (0.68) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL14214726 0.77 KDM4E (0.50) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL28104565 0.71 MAPT (0.54) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL16739706 0.69 KCNH2 (0.48) BMI1MAPTGAAALDH1A1KCNH2
SCHEMBL6652827 0.69 MAPK13 (0.73) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL16739660 0.67 SCN9A (0.84) BMI1KCNH2SCN5ASCN9A
SCHEMBL6290887 0.67 MAPT (0.59) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL16747950 0.67 SCN9A (0.54) BMI1MAPTGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885MAPT 4579/4885GAA 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.